To review and evaluate the literature relative to the use of herbal therapies in the treatment of benign prostatic hyperplasia.
DATA SOURCES:
Literature was identified by MEDLINE, Embase, International Pharmaceutical Abstracts, and the International Bibliographic Information on Dietary Supplements searches and through cross-referencing of selected articles.
STUDY SELECTION/DATA EXTRACTION:
All articles identified from the data sources were evaluated and all information deemed relevant was included in this review.
DATA SYNTHESIS:
A large percentage of men >50 years old begin to experience signs and symptoms of benign prostatic hyperplasia (BPH). Herbs hold promise in the treatment of BPH. Serenoa repens, Pygeum africanum, Urtica dioica radix, and Cucurbita peponis semen are some of the botanical therapies used in the treatment of BPH.
CONCLUSIONS:
There are many European studies examining efficacy, dose, and adverse effects of these plants in the treatment of BPH. However, numerous questions remain. These include issues concerning long-term beneficial and adverse effects of herbal therapy, prevention of complications, standardization of extracts, and concomitant use with “mainstream” medications. Based on the information available today, these botanical therapies can be used for treatment of a number of objective and subjective symptoms in patients with BPH, stages I and II.
ThompsonJF. Geriatric urologic disorders. Benign prostatic hyperplasia. In: Koda-KimbleMAYoungLYKradjanWAGuglielmoBJ, eds. Applied therapeutics: The clinical use of drugs. 7th ed.Philadelphia: Lippincott Williams & Wilkins, 2001;99: 15–24.
2.
LeeM. Management of benign prostatic hyperplasia. In: DiPiroJTTalbertRLYeeGCMatzkeGRWellsBGPoseyLM, eds. Pharmacotherapy: A pathophysiologic approach. 5th ed.New York: McGraw Hill, 2002: 1533–42.
3.
StroheckerJTrivieriLLewisD, eds. Alternative medicine: the definitive guide. Tiburon, CA: Future Medicine Publishing;1997: 733–6.
4.
EisenbergDMDavisRBEttnerSLAppelSWilkeySVan RompayMTrends in alternative medicine use in the United States, 1990–1997. JAMA1998;280: 1569–74.
5.
BlumenthalM, ed. The complete German Commission E Monographs: therapeutic guide to herbal medicines. Trans. KleinS. Boston, MA: American Botanical Council, 1998.
6.
WiltTJIshaniAStarkGMacDonaldRLauJMulrowC. Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review. JAMA1998;280: 1604–9.
7.
NewallCAAndersonLAPhilpsonJD. Herbal medicine: a guide for healthcare professionals. London: The Pharmaceutical Press, 1996.
KrzeskiTKazonMBorkowskiAWiteskaAKuczeraJ. Combined extracts of Urtica dioica and Pygeum africanum in the treatment of benign prostatic hyperplasia: Double-blind comparison of two doses. Clin Ther1993;15: 1011–20.
10.
BraeckmanJ. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: A multicenter open study. Curr Ther Res1994;55: 776–85.
11.
Saw palmetto. Pygeum. Nettles. In: Der MarderosianABeutlerJA, eds. The review of natural products. St. Louis: Facts and Comparisons, 2002.
12.
LeungAYFosterS. Encyclopedia of common natural ingredients used in food, drugs and cosmetics. 2nd ed.New York: John Wiley & Sons, 1996: 467–9.
ErnstE. Herbal medications for common ailments in the elderly. Drugs Aging1999;15: 423–8.
15.
FetrowCWAvilaJR. Professional's handbook of complementary and alternative medicines. Springhouse, PA: Springhouse Corporation, 1999.
16.
Di SilverioFFlammiaGPSciarraACaponeraMMauroMBuscariniMPlant extracts in BPH. Minerva Urol Nefrol1993;45: 143–9.
17.
Di SilverioFD'EramoGLubranoCFlammiaGPSciarraAPalmaEEvidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol1992;21: 309–14.
18.
DiPaolaRSZhangHLambertGHMeekerRLicitraERafiMMClinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med1998;339: 785–91.
19.
TenoverJS. Prostates, pates, and pimples. The potential medical uses of steroid 5 alpha-reductase inhibitors. Endocrinol Metab Clin North Am1991;20: 893–909.
20.
MetcalfBWLevyMAHoltDA. Inhibitors of steroid 5 alpha-reductase in benign prostatic hyperplasia, male pattern baldness and acne. Trends Pharmacol Sci1989;10: 491–5.
21.
PloskerGLBrogdenRN. Serenoa repens (Permixon): A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging1996;9: 379–95.
22.
Di SilverioFMontiSSciarraAVarasanoPAMartiniCLanzaraSEffects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate1998;37: 77–83.
23.
LevinRMDasAK. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol Res2000;28: 201–9.
24.
BayneCWRossMDonnellyFHabibFK. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol2000;164: 876–81.
25.
BayneCWDonnellyFRossMHabibFK. Serenoa repens (Permixon): A 5 alpha-reductase types I and II inhibitor — New evidence in a coculture model of BPH. Prostate1999;40: 232–41.
26.
Di SilverioFD'EramoGLubranoCFlammiaGPSciarraAPalmaEEvidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol1992;21: 309–14.
27.
GoepelMHeckerUKregeSRubbenHMichelM. Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro. Prostate1999;38: 208–15.
28.
GutierrezMde BotoGarcia MJCantabranaBHidalgoA. Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle. Gen Pharmacol1996;27: 171–6.
29.
Paubert-BraquetMRichardsonFOServent-SaezNGordonWCMongeMCBazanNGEffect of Serenoa repens extract (Permixon) on estradiol/testosterone—induced experimental prostate enlargement in the rat. Pharmacol Res1996;34: 171–9.
30.
RobbersJETylerVE. Tyler's herbs of choice: the therapeutic use of phytomedicinals. New York: Haworth Herbal Press, 1999: 103–6.
ChampaultGPatelJCBonnardAM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol1984;18: 461–2.
33.
GerberGS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol2000;163: 1408–12.
34.
Reece-SmithHMemonASmartCJDewburyK. The value of Permixon in benign prostatic hypertrophy. Br J Urol1986;58: 36–40.
BoylePRobertsonCLoweFRoehrbornC. Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology2000;55: 533–9.
37.
StepanovVNSiniakovaLASarrazinBRaynaudJP. Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: A double-blind comparison of two dosage regimens. Adv Ther1999;16: 231–41.
38.
CarbinBELarssonBLindahlO. Treatment of benign prostatic hyperplasia with phytosterols. Br J Urol1990;66: 639–41.
39.
DescotesJLRambeaudJJDeschaseauxPFaureG. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest1995;9: 291–7.
40.
CarraroJCRaynaudJPKochGChisholmGDDi SilverioFTeillacP. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. Prostate1996;29: 231–40.
41.
PloskerGLBrogdenRN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging1996;9: 379–95.
42.
StrauchGPerlesPVergultGGabrielMGibelinBCummingsSComparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol1994;26: 247–52.
43.
CasarosaCdi CoscioCosci MFrattaM. Lack of effects of a lyposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone. Clin Ther1988;10: 585–8.
44.
GerberGSZagajaGPBalesGTChodakGWContrerasBA. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: Effects on urodynamic parameters and voiding symptoms. Urology1998;51: 1003–7.
45.
TascaABarulliMCavazzanaAZattoniFArtibaniWPaganoF. [Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo.] Italian. Minerva Urol Nefrol1985;37: 87–91.
46.
GrassoMMontesanoABuonaguidiACastelliMLaniaCRigattiPComparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol1995;48: 97–103.
47.
SeminoAdriazola MOrtegaLozano JLCoboGarcia EBañezTejeda ERodriguezRomero F. [Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and Serenoa repens.] Spanish. Arch Esp Urol1992;45: 211–3.
48.
SchneiderHJHonoldEMasuhrT. [Treatment of benign prostatic hyperplasia. Results of a treatment study with the phytogenic combination of Sabal extract WS 1473 and Urtica extract WS 1031 in urologic specialty practices.] German. Fortschr Med1995;113: 37–40.
49.
MarksLSTylerVE. Saw palmetto extract: Newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia. Urology1999;53: 457–61.
50.
OndrizekRRChanPJPattonWCKingA. Inhibition of human sperm motility by specific herbs used in alternative medicine. J Assist Reprod Genet1999;16: 87–91.
51.
OndrizekRRChanPJPattonWCKingA. An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid. Fertil Steril1999;71: 517–22.
52.
SchulzVHanselRTylerVE. Rational phytotherapy: a physician's guide to herbal medicine. 3rd ed.Berlin: Springer, 1998: 228–33.
53.
AndroMCRiffaudJP. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: A review of 25 years of published experience. Curr Ther Res1995;56: 796–817.
54.
BarletAAlbrechtJAubertAFischerMGrofFGrothuesmannHG[Efficacy of Pygeum africanum extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: Evaluation of objective and subjective parameters. A placebo-controlled, double-blind, multicenter study.] German. Wien Klin Wochenschr1990;102: 667–73.
55.
BrezaJDzurnyOBorowkaAHanusTPetrikRBlaneGEfficacy and acceptability of Tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): A multicentre trial in central Europe. Curr Med Res Opin1998;14: 127–39.
56.
ThieblotLBerthelaySBerthelayJ. [Preventive and curative action of a bark extract from an African plant, Pygeum africanum, on experimental prostatic adenoma in rats.] French. Therapie1971;26: 575–80.
57.
PieriniNCittiFDi MarzioSPozzatoCQuerciaV. [Identification and determination of N-docosanol in the bark extract of Pygeum africanum and in patent medicines containing it.] Italian. Boll Chim Farm1982;121: 27–34.
58.
LongoRTiraS. Steroidal and other components of Pygeum africanum bark. Farmaco [Prat]1983;38: 287–92.
59.
MartinelliEM. Characterization of Pygeum africanum bark extracts by HRGC with computer assistance. High Res Gas Chrom Capil Chrom1986;9: 106–10.
60.
MuntzingJEnerothPGustafssonJALiljekvistJ. Direct and indirect effects of docosanol (IK.2), the active principle in Tadenan, on the rat prostate. Invest Urol1979;17: 176–80.
61.
LevinRMDasAKHaugaardNNovitskyYHoranPLeggettREBeneficial effects of Tadenan therapy after two weeks of partial obstruction in the rabbit. Neurourol Urodyn1997;16: 583–99.
62.
YablonskyFNicolasVRiffaudJPBellamyF. Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts. J Urol1997;157: 2881–7.
63.
RhodesLPrimkaRLBermanCVergultGGabrielMPierre-MaliceMComparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate1993;22: 43–51.
64.
DutkiewiczSKalczakM. Quantitative—comparative histology of prostatic adenomas in medically and surgically treated patients. Int Urol Nephrol1994;26: 455–60.
65.
MatheGOrbach-ArbouysSBiziECourtB. The so-called phyto-estrogenic action of Pygeum africanum extract. Biomed Pharmacother1995;49: 339–40.
66.
MatheGHallardMBourutCHChenuE. A Pygeum africanum extract with so-called phyto-estrogenic action markedly reduces the volume of true and large prostatic hypertrophy. Biomed Pharmacother1995;49: 341–3.
67.
BonatiA. How and why should we standardize phytopharmaceutical drugs for clinical validation?J Ethnopharmacol1991;32: 195–7.
68.
ChatelainCAutetWBrackmanF. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: A randomized, double-blind study, with long-term open label extension. Urology1999;54: 473–8.
69.
DonkervoortTSterlingAvan NessJ. A clinical and urodynamic study of Tadenan in the treatment of benign prostatic hypertrophy. Eur Urol1977;3: 218–25.
70.
DufourBChoquenetCRevolMFaureGJorestR. [Controlled study of the effects of Pygeum africanum extract on the functional symptoms of prostatic adenoma.] French. Ann Urol (Paris)1984;18: 193–5.
71.
Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scientific Co-op Phytother, 1997.
72.
FosterSTylerVE. Tyler's honest herbal: a sensible guide to the use of herbs and related remedies. 3rd ed.. Binghamton, NY: Haworth Herbal Press, 1993: 105–6.
73.
BissetNG, ed. Herbal drugs and phytopharmaceuticals: a handbook for practice on a scientific basis. Stuttgart: Medpharm GmbH Scientific Publishers, 1994.
74.
GruenwaldJBrendlerTJaenickeC, eds. PDR for herbal medicines. 1st ed.Montvale, NJ: Medical Economics, 1998: 784–5.
75.
ZiyyatALegssyerAMekhfiHDassouliASerhrouchniMBenjellounW. Phytotherapy of hypertension and diabetes in oriental Morocco. J Ethnopharmacol1997;58: 45–54.
76.
BasaranAAYuTWPlewaMJAndersonD. An investigation of some Turkish herbal medicines in Salmonella typhimurium and in the COMET assay in human lymphocytes. Teratog Carcinog Mutagen1996;16: 125–38.
77.
LichiusJJLenzCLindemannPMullerHAumullerGKonradL. Antiproliferative effect of a polysaccharide fraction of a 20% methanolic extract of stinging nettle roots upon epithelial cells of human prostate (LNCaP). Pharmazie1999;54: 768–71.
78.
HiranoTHommaMOkaK. Effects of stinging nettle root extracts and their steroidal components on the Na+, K+-ATPase of the benign prostatic hyperplasia. Planta Med1994;60: 30–3.
79.
KonradLMullerHLenzCLaubingerHAumullerGLichiusJJ. Antiproliferative effect on human prostate cancer cells by a stinging nettle root (Urtica dioica) extract. Planta Medica2000;66: 44–7.
80.
VontobelHPHerzogRRutishauserGKresH. [Ergebnisse einer Doppelblindstudie über die Wirksamkeit von ERU-Kapseln in der knoservativen Behandlung der benignen Prostatahyperplasie.] German. Urologe [A]24:49–61, 1985.
81.
Dathe G, Schmid H [Phytotherapie der benignen Prostatahyperplasie (BPH). Doppelblindstudie mit Extraktum Radicis Uricae (ERU).] German. Urologie [B]1987;27: 223–36.
82.
BergesRRWindelerJTrampischHJSengeTHAeikensBAlbrechtJRandomised, placebo-controlled, double-blind clinical trial of beta-sterol in patients with benign prostatic hyperplasia. Lancet1995;345: 1529–32.
83.
KlipelKFHiltlDMSchippB. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Br J Urol1997;80: 427–32.
84.
BergesRRKassenASengeT. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: An 18-month follow-up. BJU Int2000;85: 842–6.
85.
ThomasJA. Diet, micronutrients, and the prostate gland. Nutr Rev1999;57: 95–103.
86.
MarksLPartinAWEpsteinJITylerVESimonIMacairanML. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol2000;163: 1451–6.
87.
SokelandJ. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: Analysis of prostate volume and therapeutic outcome. BJU Int2000;86: 439–42.
88.
FriederichMTheurerCSchiebel-SchlosserG. [Prosta Fink Forte capsules in the treatment of benign prostatic hyperplasia. Multicentric surveillance study in 2245 patients.] German. Forsch Komplementarmed Klass Naturheilk2000;7:4:200–4.
89.
HamidSRojterSVierlingJ. Protracted cholestatic hepatitis after the use of Prostata. Ann Intern Med1997;127: 169–70.
